Renaissance Technologies (RenTech)'s AMRX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 276,637 shares of Amneal Pharmaceuticals, Inc. (AMRX) worth $3.44 M, representing 0.01% of the portfolio. First purchased in 2018-Q3, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in AMRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 573,000 shares. Largest reduction occurred in Q1 2019, reducing 566,300 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Amneal Pharmaceuticals (AMRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amneal Pharmaceuticals (AMRX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +260,237 | Add 1586.81% | 276,637 | $12.43 |
| Q4 2025 | -73,500 | Reduce 81.76% | 16,400 | $12.60 |
| Q3 2025 | -338,100 | Reduce 79.00% | 89,900 | $10.01 |
| Q2 2025 | -196,700 | Reduce 31.49% | 428,000 | $8.09 |
| Q1 2025 | -61,800 | Reduce 9.00% | 624,700 | $8.38 |
| Q4 2024 | -69,100 | Reduce 9.15% | 686,500 | $7.92 |
| Q3 2024 | +72,900 | Add 10.68% | 755,600 | $8.32 |
| Q2 2024 | +149,970 | Add 28.15% | 682,700 | $6.35 |
| Q1 2024 | +324,930 | Add 156.37% | 532,730 | $6.06 |
| Q4 2023 | +93,700 | Add 82.12% | 207,800 | $6.07 |
| Q3 2023 | +114,100 | New Buy | 114,100 | $4.22 |
| Q1 2023 | -76,400 | Sold Out | 0 | $0.00 |
| Q4 2022 | -65,500 | Reduce 46.16% | 76,400 | $0.00 |
| Q3 2022 | -30,500 | Reduce 17.69% | 141,900 | $2.02 |
| Q2 2022 | +103,800 | Add 151.31% | 172,400 | $3.18 |
| Q1 2022 | +68,600 | New Buy | 68,600 | $4.17 |
| Q2 2021 | -448,660 | Sold Out | 0 | $0.00 |
| Q1 2021 | +276,111 | Add 160.02% | 448,660 | $6.73 |
| Q4 2020 | +172,549 | New Buy | 172,549 | $4.57 |
| Q3 2019 | -71,700 | Sold Out | 0 | $0.00 |
| Q2 2019 | -315,700 | Reduce 81.49% | 71,700 | $7.17 |
| Q1 2019 | -566,300 | Reduce 59.38% | 387,400 | $14.17 |
| Q4 2018 | +573,000 | Add 150.51% | 953,700 | $13.53 |
| Q3 2018 | +380,700 | New Buy | 380,700 | $22.19 |
Renaissance Technologies (RenTech)'s Amneal Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Amneal Pharmaceuticals, Inc. (AMRX) in Q3 2018, acquiring 380,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Amneal Pharmaceuticals, Inc. (AMRX) for 24 quarters since Q3 2018.
Renaissance Technologies (RenTech)'s largest addition to Amneal Pharmaceuticals, Inc. (AMRX) was in Q4 2018, adding 953,700 shares worth $12.9 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 276,637 shares of Amneal Pharmaceuticals, Inc. (AMRX), valued at approximately $3.44 M.
As of the Q1 2026 filing, Amneal Pharmaceuticals, Inc. (AMRX) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Amneal Pharmaceuticals, Inc. (AMRX) was 953,700 shares, as reported at the end of Q4 2018.